Haleon plc: Total Voting
Rights and Capital
21
March 2024: Haleon plc ("Haleon" or
the "Company) announces that the Company has today cancelled
102,272,727 ordinary
shares of £0.01 each, repurchased from Pfizer Inc.
As at 21 March 2024 the total number
of shares issued by Haleon plc with rights to vote is
9,132,301,104 ordinary
shares of £0.01 each. There are no ordinary shares held in
Treasury.
The figure of 9,132,301,104 may be used by
shareholders (and others with notification obligations) as the
denominator for the calculation by which they will determine if
they are required to notify their interest in, or a change to their
interest in, the Company under the FCA's Disclosure Guidance and
Transparency Rules.
The person responsible for arranging
the release of this announcement on behalf of Haleon is Amanda
Mellor, Company Secretary.
About Haleon
Haleon (LSE / NYSE: HLN) is a global
leader in consumer health, with a purpose to deliver better
everyday health with humanity. Haleon's product portfolio spans
five major categories - Oral Health, Pain Relief, Respiratory
Health, Digestive Health and Other, and Vitamins, Minerals and
Supplements (VMS). Its long-standing brands - such as Advil,
Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident,
parodontax and Centrum - are built on trusted science, innovation
and deep human understanding.
For more information, please
visit www.haleon.com.